Monitoring of everolimus trough concentrations for achieving optimal tolerance in the management of tuberous sclerosis complex

Pediatr Neurol. 2014 Sep;51(3):e9-10. doi: 10.1016/j.pediatrneurol.2014.05.019. Epub 2014 May 29.

Authors

Manuel F Landecho¹, Felix Alegre², Juan Felipe Lucena², Ana Huerta², Nerea Fernández-Ros², Azucena Aldaz³

Affiliations

¹ Unidad de Médicos Hospitalistas-Área de Hospitalización Especial, Departamento de Medicina Interna, Clínica Universidad de Navarra, Pamplona, Navarra, España. Electronic address: [email protected].
² Unidad de Médicos Hospitalistas-Área de Hospitalización Especial, Departamento de Medicina Interna, Clínica Universidad de Navarra, Pamplona, Navarra, España.
³ Servicio de Farmacia, Clínica Universidad de Navarra, Pamplona, Navarra, España.

PMID: 24986682
DOI: 10.1016/j.pediatrneurol.2014.05.019

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Adult
Drug Monitoring / methods*
Everolimus / administration & dosage*
Everolimus / blood
Female
Humans
Kidney / diagnostic imaging
Kidney / drug effects
Protein Kinase Inhibitors / administration & dosage*
Protein Kinase Inhibitors / blood
TOR Serine-Threonine Kinases / antagonists & inhibitors
Tomography, X-Ray Computed
Treatment Outcome
Tuberous Sclerosis / diagnostic imaging
Tuberous Sclerosis / drug therapy*

Substances

Protein Kinase Inhibitors
Everolimus
MTOR protein, human
TOR Serine-Threonine Kinases